Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company C.R. Bard (BCR) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at C.R. Bard and see what CAPS investors are saying about the stock right now.
C.R. Bard facts
|
|
Headquarters (founded) |
Murray Hill, N.J. (1907) |
Market Cap |
$8.1 billion |
Industry |
Healthcare equipment |
Trailing-12-Month Revenue |
$3.0 billion |
Management |
Chairman/CEO Timothy Ring President/COO John Weiland |
Return on Equity (average, past 3 years) |
23% |
Cash/Debt |
$896.3 million / $1.4 billion |
Dividend Yield |
0.8% |
Competitors |
Boston Scientific Johnson & Johnson |
On CAPS, 97% of the 279 members who have rated C.R. Bard believe the stock will outperform the S&P 500 going forward.
Earlier this week, one of those Fools, All-Star JohnCLeven, succinctly summed up the C.R. Bard bull case for our community:
[C.R. Bard] has been on my radar for a while. [C.R. Bard] exhibits many of the characteristics that I find appealing in a business including: high returns on capital and equity, consistent growth in earnings and free cash flows, share buybacks, and a solid balance sheet.
[C.R. Bard] has a solid position within the medical device industry, and I believe that probability is very high that [C.R. Bard] will continue to create significant value over the next 5-10 years, and probably much longer. At today's 6.8% free cash flow yield, this high-quality business should outperform in the long run.